Interferon-Î³ release assays (IGRAs) such as QFT gold plus is one of the main toolsrnfor the diagnosis of latent TB infection (LTBI). The main objective this study was tornassess the effect of Rifapentin and Isoniazid (3HP) on IGRA reversion andrnconversion. rnIGRA reversion and conversion rates have generally been reported after preventivernTB therapy, but rates vary widely depending on different settings and there was nornstudy conducted in Ethiopia on IGRA reversion and conversion in post 3HP. rnA retrospective cohort study of 519 human immunodeficiency virus (HIV) positivernindividuals who had follow up at Zewditu and Alert Hospitals in Addis Ababa,rnEthiopia underwent testing with QuantiFERON (QFT) gold plus at enrolment andrn12-month follow-up after taking Rifapentine and Isoniazid (3HP) prophylaxisrntherapy were included in the final analysis in this study to assess the reversion andrnconversion of IGRA. rnThe rate of IGRA reversion among LTBI positives and the rate of conversion amongrnlatent Tuberculosis infection (LTBI) negative at baseline was 67/169 (39.6 %) andrn66/350 (18.9 %) respectively. The observed high IGRA conversion rates indicated arnhigher rate of Mycobacterium TB infection among LTBI negative patients despiterntaking 3HP. The prevalence of LTBI among HIV positive individuals was found tornbe 169/519 (32.6 %; 95% CI 28.5% to 36.5%). Having a history of tuberculosis isrnsubstantially associated with LTBI (AOR=1.7 [95% CI 1.15, 2.52]). rnIGRA reversion rate after taking Rifapentin â€“ INH prophylaxis therapy was fairlyrnhigh and the rate of IGRA conversion was high despite taking the tuberculosisrnprophylaxis. Hence targeted screening approach for diagnosing latent tuberculosisrninfection in HIV/AIDS patients using appropriate methods before administration ofrnTB preventive therapy is recommended.